Trial reportNature communications2019
Schistosoma mansoni treatment reduces HIV entry into cervical CD4+ T cells and induces IFN-I pathways.
Trial report in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data.BMC medicine · 2022Pooled it
- Effects of schistosomes on host anti-viral immune response and the acquisition, virulence, and prevention of viral infections: A systematic review.PLoS pathogens · 2021Pooled it
- Association of schistosomiasis and HIV infections: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- A systematic review and meta-analysis to assess the association between urogenital schistosomiasis and HIV/AIDS infection.PLoS neglected tropical diseases · 2020Pooled it
- Cervicovaginal Immune Activation in Zambian Women With Female Genital Schistosomiasis.Frontiers in immunology · 2021Trial
- Schistosome Infection is Associated With High-Risk Human Papillomavirus Persistence, Together With Altered Cervicovaginal Microbiota.The Journal of infectious diseases · 2026Article
- Helminth Coinfections Modulate Disease Dynamics and Vaccination Success in the Era of Emerging Infectious Diseases.Vaccines · 2025Review
- Predicting Prognosis and Immunotherapy Response in Glioblastoma (GBM) With a 5-Gene CAF-Risk Signature.Cancer reports (Hoboken, N.J.) · 2025Article
- Quantitative profiling of the vaginal microbiota improves resolution of the microbiota-immune axis.Microbiome · 2025Article
- Sex as a biological variable in HIV-1 and schistosome co-infection.The lancet. HIV · 2025Review
- Beyond schistosomiasis: unraveling co-infections and altered immunity.Clinical microbiology reviews · 2024Review
- Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo.Nature communications · 2023Article
- Increased HIV Incidence inPathogens (Basel, Switzerland) · 2023Article
- Article
- DoesCells · 2021Review
- Female Genital Schistosomiasis and HIV-1 Incidence in Zambian Women: A Retrospective Cohort Study.Open forum infectious diseases · 2021Article
- Schistosomiasis is associated with rectal mucosal inflammation among Kenyan men who have sex with men.International journal of STD & AIDS · 2021Article
- Prevalence of Schistosoma mansoni infection in Ethiopia: a systematic review and meta-analysis.Tropical diseases, travel medicine and vaccines · 2021Review
- Associations between schistosomiasis and HIV-1 acquisition risk in four prospective cohorts: a nested case-control analysis.Journal of the International AIDS Society · 2020Article
- The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.Trends in parasitology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
Abstract
Schistosoma mansoni (Sm) infection has been linked with an increased risk of HIV acquisition in women. Therefore, defining the mechanism(s) by which Sm alters HIV susceptibility might lead to new HIV prevention strategies. Here, we analyze the impact of standard Sm therapy in HIV-uninfected Sm+ Ugandan adult women on genital HIV susceptibility and mucosal and systemic immunology. Schistosomiasis treatment induces a profound reduction of HIV entry into cervical and blood CD4+ T cells that is sustained for up to two months, despite transient systemic and mucosal immune activation and elevated genital IL-1α levels. Genital IFN-α2a levels are also elevated post-treatment, and IFN-α2a blocks HIV entry into primary CD4+ T cells ex vivo. Transcriptomic analysis of blood mononuclear cells post-Sm treatment shows IFN-I pathway up-regulation and partial reversal of Sm-dysregulated interferon signaling. These findings indicate that Sm therapy may reduce HIV susceptibility for women with Sm infection, potentially through de-repression of IFN-I pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.